格隆汇1月22日｜博腾股份(300363.SZ)公告称，博腾股份发布2025年度业绩预告，预计归属于上市公司 股东的净利润为8,000万元~10,500万元，同比扭亏为盈。报告期内，公司预计实现营业收入33.5亿~35亿 元，同比增长11%~16%，收入增长主要由临床三期至商业化阶段的项目需求驱动。盈利增长主要得益 于营业收入增长带来的规模效应、降本增效和精益运营提升毛利率、费用稳中有降，以及资产减值损失 同比大幅减少。 ...

证券之星消息，1月22日化学制药板块较上一交易日下跌1.01%，益方生物领跌。当日上证指数报收于 4122.58，上涨0.14%。深证成指报收于14327.05，上涨0.5%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 605177 | 东亚药业 | 22.95 | 6.89% | 6.39万 | | 1.45亿 | | 688799 | 华纳药厂 | 50.35 | 6.52% | 7.58万 | | 3.74亿 | | 600851 | 海欣股份 | 8.00 | 5.26% | 52.68万 | | 4.27亿 | | 002898 | *ST赛隆 | 14.16 | 4.97% | - 3.32万 | | 4572.87万 | | 688356 | 键凯科技 | 107.48 | 3.29% | 1.27万 | | 1.36亿 | | 300401 | 化园生物 | 18.61 | 3.10% | 40.89万 | | 7.64亿 | | ...

Core Viewpoint - East Asia Pharmaceutical (605177.SH) forecasts a net loss attributable to shareholders of 75 million to 90 million yuan for the fiscal year 2025 [1] Group 1: Financial Performance - The company anticipates a net loss of 75 million to 90 million yuan for 2025 [1] Group 2: Product Development - During the reporting period, the company has applied for a batch of new approvals for raw materials and formulations [1] - The company has obtained its first formulation approval for Levofloxacin tablets, marking a significant breakthrough in its integrated development strategy of raw materials and formulations [1] - This approval will enrich the company's product line, enhance its competitiveness, and promote sustainable, stable, and healthy development [1] - The experience gained from this approval will be valuable for future formulation registration certificate applications [1]

Core Viewpoint - The company Minohua announced that its subsidiaries Xuancheng Minohua, Innovation Research Institute, and Minohua Tiankang have received the "High-tech Enterprise Certificate," which is valid for three years [1] Group 1 - Xuancheng Minohua's certificate is effective until October 28, 2025, while the Innovation Research Institute and Minohua Tiankang's certificates are effective until December 26, 2025 [1] - The recognition is a re-certification following the expiration of the previous certificates [1] - The three subsidiaries will be able to pay corporate income tax at a rate of 15% from 2025 to 2027 [1]

Group 1 - The company expects to achieve a net profit attributable to shareholders of the parent company between 50 million to 65 million yuan for the year 2025, representing an increase of 20.5755 million to 35.5755 million yuan compared to the same period last year, which translates to a year-on-year growth of 69.93% to 120.9% [1] - The main reasons for the performance change include the company's continuous promotion of refined management and technological upgrades, which further optimized operational efficiency and cost structure [1] - The company has deepened its differentiated competitive strategy and increased market expansion efforts, seizing market opportunities to enhance overall profitability [1]

Group 1 - The controlling shareholder Huibang Zhuoyuan has notified that it will release the pledge of 10.6 million shares, which accounts for 2.86% of its holdings and 0.54% of the company's total share capital [1] - The pledge was initiated on May 31, 2023, and is set to be released on January 21, 2026 [1] - As of the announcement date, Huibang Zhuoyuan and its concerted actors have a total of 254 million shares pledged, representing 46.80% of their holdings and 12.83% of the company's total share capital [1]

智通财经APP讯，恩华药业(002262.SZ)公告，公司近日获得国家药品监督管理局核准签发的化学药品右 酮洛芬氨丁三醇注射液的《药品注册证书》。右酮洛芬氨丁三醇注射液是一种非甾体抗炎镇痛药，是 COX-1和COX-2活性的抑制剂，作为阿片类镇痛药的辅助，用于成人不适合口服给药的急性中度至重度 术后疼痛。 ...

Group 1 - The core viewpoint of the articles highlights the positive signals released by JPM meetings, reinforcing the industrial positioning of AI in healthcare [1] - AI in pharmaceuticals is enhancing the entire drug development process, improving efficiency and success rates in new drug discovery, preclinical screening, clinical development, and production, indicating a high growth trajectory in the future [1] - Since the beginning of 2026, multinational pharmaceutical companies have engaged in over 9 AI-related collaborations, totaling more than $6 billion [1] Group 2 - Chinese innovative pharmaceutical companies are demonstrating competitive strength, with a surge in outbound business development for dual antibodies, ADCs, and GLP-1RA new drugs expected by 2025 [1] - The investment direction in AI healthcare includes areas such as AI health management, AI medical information technology, AI medical imaging, AI surgical robots, AI gene sequencing, and AI pharmaceuticals [1] - The Guotai Innovation Drug ETF (589720) tracks the Innovation Drug Index (950161), which has a daily price fluctuation limit of 20%, focusing on listed companies dedicated to innovative drug research and development in the biopharmaceutical and chemical pharmaceutical sectors [1]

（文章来源：证券日报） 证券日报网讯 1月21日，金凯生科在互动平台回答投资者提问时表示，截至2026年1月20日，公司股东 数为14722户。 ...

Core Viewpoint - Fujilai (301258) anticipates that its Shandong project will be completed by 2026, but the initial phase of production typically involves challenges such as capacity ramp-up, equipment debugging, and customer validation, leading to uncertainty in short-term performance contributions [1] Group 1 - The new project is expected to face challenges in the first two years, including insufficient capacity utilization, high fixed cost allocation, and market development cycles [1] - There is a certain period from production to reaching capacity and from reaching capacity to profitability, which may affect short-term performance [1] - Investors are advised to pay attention to investment risks, and specific operational data should be referenced from the company's periodic reports [1]